Meeting
2015 Genitourinary Cancers Symposium
Opioid use among prostate cancer patients with bone metastases.
Authors
Avin Yaldo
Bayer HealthCare Pharmaceuticals, Wayne, NJ
Avin Yaldo , Lonnie Kent Wen , Augustina Ogbonnaya , Adriana Valderrama , Jonathan K Kish , Michael Eaddy , Charles Kreilick , Brian S. Seal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 278)
DOI
10.1200/jco.2015.33.7_suppl.278
Abstract #
278
Poster Bd #
D21
Abstract Disclosures
Similar Posters
Poster
2015 Breast Cancer Symposium
Bone targeting agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the US.
First Author: David H. Henry
Poster
2012 Genitourinary Cancers Symposium
Randomized study on the effect of zoledronic acid treatment for prostate cancer with bone metastasis during initial combined androgen blockade.
First Author: Satoru Ueno
Poster
2011 ASCO Annual Meeting
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain.
First Author: N. D. Shore
Poster
2024 ASCO Annual Meeting
Bone metastases and skeletal related events in patients with gastrointestinal neuroendocrine tumors.
First Author: Paula Bruges